23 3 2007 5 IMMUNOLOGICAL JOURNAL Vol. 23 No. 3 May. 2007 287 [ ]100028861 (2007) 0320287205 MSCs 1, 2, 1, 1 1 3, (1., 400038 ;2., 400038) [ ] (MSCs) MSCs ; MSCs (PHA),H 3 2TdR MSCs,CD29 CD105 CD166,CD14 CD34 CD45 ; MSCs PHA MSCs [ ] ; ; [ ] R392 [ ] A Immune regulatory effects of mesenchymal stem cells derived from human umbilical blood WANG Meng, YANG Yuan, YANG Dong2ming, WANG Xu2quan, XU Jian2zhong ( Orthopedic Center of PLA, Southwest Hospital, Third Military Medical University, Chongqing 400038) [ Abstract] Objective To study the isolation, expansion, and purification of mesenchymal stem cells (MSCs) from human umbilical cord blood, and investigate its immune regulatory effects on homologous lymphocyte.methods Human umbilical cord blood samples were ob2 tained sterilely. The cord blood mononuclear cells were isolated by lymphocyte separation medium and individual colonies were selected and cul2 tured. The phenotype of MSCs derived from umbilical blood was analyzed by flow cytometry. The MSCs derived from umbilical blood were added to mixed lymphocyte cultures and PHA2induced transformation cultures with various concentrations. The proliferation of lymphocyte was mea2 sured by [ 3 H]2thymidine incorporation using a liquid scintillation counter. Effects of MSCs derived from umbilical blood on mixed lymphocyte response and PHA2induced lymphocyte transformation were investigated. Results The adherent cells isolated from the cord blood mononuclear cells displayed a fibroblast2like morphology and expressed several MSCs2related antigens CD29, CD44, and CD105, not CD34, CD45, or CD106. The MSCs derived from umbilical blood showed negative immunomodulatory effects and could inhibit evidently the mixed lymphocyte re2 sponse and PHA induced transformation. Conclusion The MSCs derived from umbilical blood with the immune regulatory effect could be an important and novel source of allogenic seed cells for bone tissue engineering. [ Key words] Umbilical cord blood ; Mesenchymal stem cells ; Immunomodulation ; Bone tissue engineering,, ( mesenchymal stem cells, [1 MSCs), ] MSCs [ ]2007-04 - 02 ;[ ]2007-04 - 13 [ ] (863 2006AA02A122) [ ] (1977 - ),, DNA 306, 100101( Tel) 0232 68771720 ; ( E2 mail) wangmen99 @yahoo. com 3, 1980,, [2 ] MSCs, MSCs
288 23,35 1 2,78 2. 1 MSCs 34 1, 80 %90 %,, (1 mmolπl EDTA),1 21 3 Mesencult TM,4872 h, 3 6 7,, ; 1. 3,, 2025 d MSCs, 20 gπl BSA PBS, 2 10 5 Π PE,, FITC CD14 CD29 CD34 CD45 CD105 CD166, 45 80 %90 % (EB ) 10 L,, 4 30 min,pbs 2,10 gπl 4,2 3 80 %, 3 30 min,facscalibur (BD ),, CellQuest (1) 812 d, 1. 4 15 MSCs,1. 077 gπl : 13 d,36 d (MNC), 200 mlπlfbs RPMI 1640,7 9 d ( Gibco ), 37, 50 mlπl CO 2 24 h C(sigma ) 25 gπml,37 50 mlπl CO 2 30 min 3 C MSCs C 1 10 4 2. 5 10 4 5 10 4 1 10 5 2 10 5 Π 24 5 10 5 Π, 5 10 5 Π 1 MSCs ( 40), 5,37 50 mlπl 96 37 kbq 3 H2 cpm 1. 5 MSCs 1 C 1 10 4 2. 5 10 4 5 10 4 1. 1 1 10 5 2 10 5 Π 24 ;,5 10 5 Π, 60120 ml, 12 h PHA(Sigma ), 30gΠmL, 0. 01 molπl ph 7. 4 PBS 1 1, PHA 1. 077 gπl,, 5,37,50 mlπl CO 2 2 500 rπmin 20 min,, PBS 2 3 d 96,pH Mesencult TM ( Stem Cell, 3 H2TdR ) 4 gπl 1. 2 1. 0 10 8 ml - 1 (Sigma ) 90 %, 37 1. 6 SPSS10. 0, t 50 mlπl CO 2, Fig 1 Mesenchymal stem cells derived from umbilical blood( 40) CO 2 4 d 2. 2 MSCs : MSCs TdR, 18 h CD29 CD105 CD166, CD14
3,1 MSCs 289 CD34 CD45 Π (2) 2 MSCs Fig 2 Identification of mesenchymal stem cells derived from umbilical blood by flow cytometry 2. 3 MSCs 10 4 2. 5 10 4 5 10 4 1 10 5 2 10 5 Π, ( cpm) 3 H2TdR cpm ( 2. 686 (61157 0. 386) 10 4 MSCs 0. 324) 10 4 (2. 071 0. 294) 10 4 (1. 876 0. 267), 10 4 (1. 34 0. 254) 10 4 (1. 252 0. 159) 10 4, MSCs 1 10 4 2. 5 10 4 5 10 4 1 10 5 MSCs 2 10 5 Π cpm (2. 603 (4) 01297) 10 4 ( 2. 166 0. 215) 10 4 ( 1. 889 01226) 10 4 ( 1. 447 0. 213) 10 4 ( 1. 229 01164) 10 4 MSCs ( P < 0. 01) MSCs, (3) 3 MSCs Fig 3 Effects of MSCs derived from umbilical blood on mixed lymphocyte reaction 2. 4 MSCs [3 ] (mesenchymal stem cell, MSCs PHA MSCs) ( P < 0. 01), MSCs, MSCs,, 3 H2TdR cpm (5. 924 4 MSCs Fig 4 Effects of MSCs derived from umbilical blood on 3 PHA2induced lymphocyte reaction MSCs 0. 651) 10 4, MSCs 1
290 23 [4 ], HLA 20 d MSCs MSCs [7,8 ] MSCs MSCs, : MSCs, MSCs MSCs : MSCs PHA, MSCs MSCs MSCs, 3 H2TdR cpm (51924 01651) 1980 10 4, MSCs 1 10 4 215 [5 10 4 5 10 4 1 10 5 2 10 5 Π, 3 H2TdR ] 2000, cpm ( 21686 01324) 10 4 Erices (21071 01294 ) 10 4 ( 11876 01267 ) 10 4 (1134 01254) 10 4 (11252 01159) 10 4, [6 MSCs ] MSCs MSCs ph Mes2 MSCs encult TM MSCs MNC,3,45 80 %90 %, 10 3 [9 ],23, [10 80 %, 3 ] :,,,,, 812 d, 15 MSCs MSCs MSCs MSCs, MSCs MSCs MSCs MSCs MSCs,, 3, 15 [ ] MSCs [1 ] Pittenger MF, Mackay AM, Beck SC,et al. Multilineage po2 : tential of adult human mesenchymal stem cells [J ]. Science, CD29 CD105 CD166, CD14 1999,284(5 411) :143-147. CD34 CD45 [2 ] Tse W, Laughlin MJ. Umbilical cord blood transplantation : a new alternative option [ J ]. Hematology Am Soc Hematol Educ Program, 2005 : 377-383. Π ( 294 )
294 23, Natl Acad Sci USA,1984, 81 (9) : 2 645-2 649. [3,5,6 ] Brinkmann [7 ] refractory hairy cell leukemia to a recombinant immunotoxin, [J ]. Blood, 1999, 94 (10) : 3 340-3 348. B3 ( Fv)2PE38KDEL [3 ] Pastan I. Targeted therapy of cancer with recombinant immu2 B3 (Fv)2PE40 notoxins[j ]. Biochim Biophys Acta,1997,1333(2) : C1 - PE C6. [8,9 ] [4 ] Kreitman RJ. Immunotoxins in cancer therapy[j ]. Curr Opin Immunol,1999,11(5) :570-578. PE38KDEL [5 ] Pastan I, Chaudhary V, FitzGerald DJ. Recombinant toxins as novel therapeutic agents[j ]. Annu Rev Biochem, 1992, 61 : 331-354. creased cytotoxic activity of Pseudomonas exotoxin and two, chimeric toxins ending in KDEL [J ]. J Biol Chem, 1991, p GEX24T21 tac,iptg 266 (26) : 17 376-17 381. GST PE38KDEL, a single2chain immunotoxin that causes complete GST regression of a human carcinoma in mice [J ]. Proc Natl Acad Sci USA, 1991, 88 (19) : 8 616-8 620. [10,11 ] PCR [8 ] Xi YZ, Zheng LY, Sun YY, et al. Molecular design and PE38KDEL GC 70 %, construction of IL26D242PE40KDEL, a novol recombinant in2 terleukin62pseudomonas exotoxin fusion protein, having tar2 geted cytotoxixity for leukemias expressing interleukin6 recep2 tors[j ]. Hum Immunol,2003,64(10 Suppl) : 247-248. p GEX24T212PE38KDEL BL21 recombinant immunotoxin with increased antitumor activity 34 % without an increase in animal toxicity[j ]. Clin Cancer Res, 2005, 11 (4) : 1 545-1 550. [10 ],,. MBL PE38KDEL [J ].,2005,21 (6) : [ ] [1 ] Gray GL, Smith DH, Baldridge JS, et al. Cloning, nucleoti2 de sequence, and expression in Escherichia coli of the exotox2 in A structural gene of Pseudomonas aeruginosa [ J ]. Proc [2 ] Kreitman RJ, Wilson WH, Robbins D, et al. Responses in [6 ] Seetharam S, Chaudhary VK, FitzGerald DJ, et al. In 2 [7 ] Brinkmann U, Pai LH, FitzGerald DJ, et al. B 3 ( Fv ) 2 [9 ] Bang S, Nanata S, Onada M, et al. HA22 ( R490A) is a 521-524. [11 ],,. SEA (D227A) [J ].,2004,20 (5) 357-360. ( ) ( 290 ) [3 ] Krampera M, Pizzolo G, Aprili G,et al. Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair [J ]. Bone, 2006, 39 (4) : 678-683. [4 ] Kneser U, Schaefer DJ, Polykandriotis E,et al. Tissue engi2 neering of bone : the reconstructive surgeon s point of view [J ]. J Cell Mol Med, 2006, 10 (1) : 7-19. [5 ] Weiss ML, Troyer DL. Stem cells in the umbilical cord [J ]. Stem Cell Rev, 2006, 2 (2) : 1552162. [6 ] Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood [ J ]. Br J Haematol, 2000, 109 (1) : 235-242. [7 ] Rocha V, Garnier F, Ionescu I, et al. Hematopoietic stem2 cell transplantation using umbilical2cord blood cells [J ]. Rev Invest Clin, 2005, 57 (2) : 314-323. [8 ],,. T [J ],2001,17 (5) : 379-382. [9 ] Kim DW, Chung YJ, Kim TG, et al. Cotransplantation of third2party mesenchymal stromal cells can alleviate single2do2 nor predominance and increase engraftment from double cord transplantation [J ]. Blood, 2004, 103 (5) : 1 941-1 948. [ 10 ] Cetrulo CL Jr. Cord2blood mesenchymal stem cells and tissue engineering [J ]. Stem Cell Rev, 2006, 2 (2) : 163-168. ( )